#4-53E. Unraveling VEXAS Syndrome: The Intersection of Somatic Mutations and Inflammation (Nat Rev Dis Primers, 2026)

Have you ever encountered an older male patient with treatment-refractory, unexplained systemic inflammation12? Today, we explore "VEXAS syndrome," a newly recognized disorder bridging hematology, immunology, and genetics1. This comprehensive review details the pathophysiology of systemic autoinflammation and clonal hematopoiesis driven by somatic mutations in the UBA1 gene within hematopoietic stem cells1. The most crucial clinical takeaway is that this research presents a paradigm shift by directly linking somatic genetic mutations to severe adult-onset inflammation, offering a genetic explanation for previously idiopathic inflammatory conditions3. However, when critically appraising this paper, clinicians must note that robust evidence, such as randomized controlled trials, and established standardized therapeutic protocols are currently lacking, meaning management remains largely empirical14. For physicians, understanding this novel concept is vital3. Recognizing VEXAS syndrome not only aids in diagnosing patients with atypical, glucocorticoid-dependent inflammatory courses but also guides appropriate genetic testing and targeted management strategies, fundamentally transforming our approach to refractory rheumatic and hematological diseases in daily practice2more_horiz.

Citation: Beck, David B., et al. VEXAS syndrome. Nature Reviews Disease Primers. 2026. DOI: https://doi.org/10.1038/s41572-026-00695-w

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.